Literature DB >> 18465246

Opioid receptor blockade improves mesenteric responsiveness in biliary cirrhosis.

Mohammad R Ebrahimkhani1, Leila Moezi, Samira Kiani, Shahin Merat, Ahmad R Dehpour.   

Abstract

Arterial vasodilation with concomitant hyperdynamic circulation is a common finding in cirrhotic subjects. Elevated levels of plasma endogenous opioid peptides have been reported in cholestasis and cirrhosis. Increased opioid peptides contribute to different manifestations of chronic liver disease such as pruritus, ascitis, and hepatic encephalopathy. In this study the potential role of opioid system in cirrhosis-induced vascular hyporesponsiveness was investigated. Bile duct ligated and sham operated animals received daily subcutaneous administration of naltrexone, an opioid receptor antagonist (20 mg/kg/day), or saline for 28 days. After 4 weeks the superior mesenteric artery was cannulated and was perfused according to McGregor method and then phenylephrine vasoconstrictor response of mesenteric vessels (10(-10) to 10(-6 )mol) was examined. In order to evaluate the effects of acute opioid receptor blockade, additional groups of animals were treated by acute single intraperitoneal naltrexone injection (20 mg/kg). Plasma level of nitrite/nitrate as an indicator for nitric oxide production was measured. Biliary cirrhosis was accompanied with a decrease in baseline perfusion pressure in mesenteric vascular bed (P < 0.01). Chronic opioid receptor blockade significantly increased this parameter (P < 0.01). The maximum pressure response to phenylephrine was decreased significantly in cirrhosis while chronic naltrexone treatment completely improved it (P < 0.01). Acute single injection of naltrexone could not influence the understudied homodynamic parameters. Chronic opioid receptor blockade did not modulate the increased nitrite/nitrate levels following cholestasis. This study provided evidence on the contribution of endogenous opioid system to vascular hyporesponsiveness in cirrhosis which is not directly correlated to high plasma NO levels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18465246     DOI: 10.1007/s10620-008-0261-7

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Mesenteric vascular bed responsiveness in bile duct-ligated rats: roles of opioid and nitric oxide systems.

Authors:  K Namiranian; M Samini; S E Mehr; S A Gaskari; H Rastegar; H Homayoun; A R Dehpour
Journal:  Eur J Pharmacol       Date:  2001-07-06       Impact factor: 4.432

2.  Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide.

Authors:  A Castro; W Jiménez; J Clària; J Ros; J M Martínez; M Bosch; V Arroyo; J Piulats; F Rivera; J Rodés
Journal:  Hepatology       Date:  1993-08       Impact factor: 17.425

3.  Mesenteric hyporesponsiveness in cirrhotic rats with ascites: role of cGMP and K+ channels.

Authors:  N M Atucha; M C Ortíz; L A Fortepiani; F J Nadal; C Martínez-Prieto; J García-Estañ
Journal:  Clin Sci (Lond)       Date:  2000-11       Impact factor: 6.124

4.  Homocysteine alterations in experimental cholestasis and its subsequent cirrhosis.

Authors:  Mohammad R Ebrahimkhani; Hamed Sadeghipour; Mehdi Dehghani; Samira Kiani; Seyedmehdi Payabvash; Kiarash Riazi; Hooman Honar; Parvin Pasalar; Naser Mirazi; Massoud Amanlou; Hassan Farsam; Ahmad R Dehpour
Journal:  Life Sci       Date:  2005-04-08       Impact factor: 5.037

5.  Opioid system blockade decreases collagenase activity and improves liver injury in a rat model of cholestasis.

Authors:  Samira Kiani; Mohammad R Ebrahimkhani; Ahmad Shariftabrizi; Behzad Doratotaj; Seyedmehdi Payabvash; Kiarash Riazi; Mehdi Dehghani; Hooman Honar; Alaleh Karoon; Massoud Amanlou; Seyed M Tavangar; Ahmad R Dehpour
Journal:  J Gastroenterol Hepatol       Date:  2007-03       Impact factor: 4.029

6.  Role of endogenous opioids in modulating HSC activity in vitro and liver fibrosis in vivo.

Authors:  S De Minicis; C Candelaresi; M Marzioni; S Saccomano; T Roskams; A Casini; A Risaliti; R Salzano; N Cautero; F di Francesco; A Benedetti; G Svegliati-Baroni
Journal:  Gut       Date:  2007-11-07       Impact factor: 23.059

7.  Do endogenous opioids contribute to the bradycardia of rats with obstructive cholestasis?

Authors:  Seyed Ali Gaskari; Ali Reza Mani; Shahram Ejtemaei-Mehr; Khodadad Namiranian; Houman Homayoun; Hossein Ahmadi; Ahmad Reza Dehpour
Journal:  Fundam Clin Pharmacol       Date:  2002-08       Impact factor: 2.748

8.  Naltrexone, an opioid receptor antagonist, attenuates liver fibrosis in bile duct ligated rats.

Authors:  M R Ebrahimkhani; S Kiani; F Oakley; T Kendall; A Shariftabrizi; S M Tavangar; L Moezi; S Payabvash; A Karoon; H Hoseininik; D A Mann; K P Moore; A R Mani; A R Dehpour
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

9.  Potentiation of anandamide effects in mesenteric beds isolated from bile duct-ligated rats: role of nitric oxide.

Authors:  Leila Moezi; Mehdi Rezayat; Morteza Samini; Hamed Shafaroodi; Shahram Ejtemaie Mehr; Mohammad R Ebrahimkhani; Ahmad R Dehpour
Journal:  Eur J Pharmacol       Date:  2004-02-13       Impact factor: 4.432

10.  Presence of the mu3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation.

Authors:  G B Stefano; A Hartman; T V Bilfinger; H I Magazine; Y Liu; F Casares; M S Goligorsky
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

View more
  2 in total

1.  Decompensated liver cirrhosis and neural regulation of mesenteric vascular tone in rats: role of sympathetic, nitrergic and sensory innervations.

Authors:  Esther Sastre; Laura Caracuel; Isabel Prieto; Pablo Llévenes; M Ángeles Aller; Jaime Arias; Gloria Balfagón; Javier Blanco-Rivero
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

2.  Ameliorative Effect of Vanillic Acid on Serum Bilirubin, Chronotropic and Dromotropic Properties in the Cholestasis-Induced Model Rats.

Authors:  Narges Atefipour; Mahin Dianat; Mohammad Badavi; Alireza Sarkaki
Journal:  Electron Physician       Date:  2016-05-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.